New collection added today:
Factor VIII or IX Concentrate Blood Products – 58 documents dealing with the marketing and distribution of contaminated AHF (anti-hemophiliac factor) blood products.
A little background: Bayer and its Cutter Laboratories manufactured AHF (anti-hemophiliac factor), a blood product used by hemophiliacs to treat uncontrolled bleeding. In the late 1960s the corporation began manufacturing AHF using pools of blood (plasma) from thousands of donors, often recruited from populations at high risk for hepatitis. In the early 1980s Cutter Laboratories realized that its AHF was contaminated with HIV but its financial investment in the product was considered too high to destroy the inventory. Cutter continued to sell the contaminated AHF to markets willing to accept it, including overseas markets in Asia and Latin America, without the recommended precaution of heat treating the product to eliminate the risk. Customers were not informed of the risk and as a consequence, hemophiliacs who infused the HIV-contaminated AHF tested positive for HIV and developed AIDS.
These documents are from class action litigation against Bayer from both US and Taiwanese plaintiffs. While "the hemo case" involved HIV-infected hemophiliacs in the United States and abroad, these documents focus on the marketing and distribution of contaminated blood products in Asia, the so-called "dumping" aspect of the larger body of cases litigated.
See all "hemo" documents
In addition to the new collection, we have also added documents to our Neurontin Marketing and Sales Practices Litigation collection, a collection of documents on the misrepresentation of Neurontin’s effectiveness. These 3 new documents are industry conducted research reports of double blind placebo controlled studies to determine the efficacy and safety of Neurontin (gabapentin) for use in migraines. Please note: These are very lengthy documents (4000+ pages) and may take a while to download.
See the Neurontin Research Reports